Photo from wikipedia
There are limited data for letermovir as primary cytomegalovirus (CMV) prophylaxis in patients less than 18 years of age. We report 9 adolescent patients who received letermovir following hematopoietic cell… Click to show full abstract
There are limited data for letermovir as primary cytomegalovirus (CMV) prophylaxis in patients less than 18 years of age. We report 9 adolescent patients who received letermovir following hematopoietic cell transplantation. No patients developed clinically significant CMV while taking letermovir. Letermovir was well tolerated and efficacious in preventing CMV infections.
Keywords:
hematopoietic cell;
following hematopoietic;
cell transplantation;
adolescent patients
Journal Title: Journal of the Pediatric Infectious Diseases Society
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of the Pediatric Infectious Diseases Society
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!